DeepMed Research

Guangdong Association of Clinical Trials

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1997-01-01

Employees: -

Market Cap: -

Website: http://gdaids.org

Clinical Trials

Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer

Phase 3

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Docetaxel
Drug: Nedaplatin
Drug: Cisplatin

First Posted Date: 2015-12-31

Last Posted Date: 2015-12-31

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 488

Registration Number: NCT02643407

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2015-03-06

Last Posted Date: 2017-06-07

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 150

Registration Number: NCT02381808

Locations: 🇨🇳
Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer

Phase 4

Conditions: Small Cell Lung Cancer

Interventions: Drug: Etoposide
Drug: Irinotecan
Drug: Cisplatin

First Posted Date: 2015-01-28

Last Posted Date: 2016-12-05

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 308

Registration Number: NCT02348450

Locations: 🇨🇳
WuHan Tongji Hospital, WuHan, Hubei, China
🇨🇳
LiaoNing Provincial Tumor Hospital, Shenyang, Liaoning, China
🇨🇳
The second affiliated hospital of zhejiang university school of medicine, Hangzhou, Zhejiang, China

and more 17 locations

Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment

Phase 2

Conditions: Small Cell Lung Cancer

Interventions: Drug: irinotecan

First Posted Date: 2014-06-24

Last Posted Date: 2021-02-03

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 54

Registration Number: NCT02171325

Locations: 🇨🇳
Jilin cancer hospital, Changchun, Jilin, China

Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients

Completed

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2014-04-15

Last Posted Date: 2017-03-01

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 250

Registration Number: NCT02113852

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

Phase 2

Terminated

Conditions: Non-small-cell Lung Cancer

Interventions: Drug: Intercalated combination of chemotherapy and erlotinib

First Posted Date: 2014-03-26

Last Posted Date: 2017-03-03

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 10

Registration Number: NCT02095782

Locations: 🇨🇳
Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

A Prospective Epidemiologic Study of ALK-Positive NSCLC in China

Completed

Conditions: Non-small-cell Lung Cancer

First Posted Date: 2014-01-22

Last Posted Date: 2017-03-01

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 3649

Registration Number: NCT02042105

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

Third-line Treatment of Gefitinib in NSCLC Patients

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Gefitinib

First Posted Date: 2013-09-02

Last Posted Date: 2020-02-06

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 46

Registration Number: NCT01933347

Locations: 🇨🇳
Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu, China

Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC

Completed

Conditions: Cell, Circulating Tumor
Carcinoma, Non-Small-Cell Lung

First Posted Date: 2012-12-04

Last Posted Date: 2016-12-05

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 180

Registration Number: NCT01740804

Locations: 🇨🇳
Guangdong general hospital, Guangzhou, Guangdong, China

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer
Brain Metastasis

Interventions: Radiation: whole brain radiation(WBI)
Drug: Icotinib

First Posted Date: 2012-11-12

Last Posted Date: 2017-03-01

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 176

Registration Number: NCT01724801

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy